Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes Axovant Gene Therapies’ (“Axovant”) positive six-month follow-up data from the second cohort of the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease. Key… Read More
Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has issued a Certificate of GMP compliance for the fourth GMP manufacturing suite within the… Read More
Oxford, UK – 17 September 2020: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2020. FINANCIAL HIGHLIGHTS • Revenue increased by 6% to £34.0 million (H1 2019: £32.1… Read More
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public… Read More
Oxford, UK – 27 August, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2020 on Thursday 17 September 2020. A virtual briefing and… Read More
Oxford, UK – 3 August 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new Development, Manufacture & License Agreement (“DMLA”) with Beam Therapeutics Inc. (“Beam”) (Nasdaq: BEAM), a Cambridge, Mass.-based biotechnology company developing… Read More
Oxford, UK – 31st July, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a three year Clinical Supply Agreement (“CSA”) with a wholly-owned subsidiary of Axovant Gene Therapies Ltd. (“Axovant”) (Nasdaq: AXGT). The CSA… Read More
Oxford, UK – 20 July, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes that AstraZeneca UK Ltd (“AstraZeneca”) has announced interim results from the ongoing Phase I/II COV001 trial, led by Oxford University on AZD1222 which showed the SARS-CoV-2… Read More
Annual General Meeting Held at the offices of Oxford Biomedica at Windrush Court, Transport Way, Oxford OX4 6LT on 23 June 2020 at 3.00 p.m. Any questions emailed to us are outlined below Q What was the process of selecting Dr Roch Doliveux as the new ChairmanA. … Read More
Oxford, UK – 23 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today provides details for the Group’s Annual General Meeting (AGM) taking place at the offices of Oxford Biomedica plc, Windrush Court, Transport Way, Oxford OX4 6LT, commencing… Read More
Oxford, UK – 19 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today provides further details for the Group’s Annual General Meeting (AGM). As announced on 22 May 2020, Oxford Biomedica is hosting its AGM on Tuesday 23 June… Read More
Oxford, UK – 9 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, has been informed by Sanofi that following completion of a company-wide portfolio review, Sanofi intends to return to Oxford Biomedica the rights to the following ophthalmology gene… Read More